Glenmark Specialty secures NMPA approval for RYALTRIS nasal spray EP News Bureau Nov 11, 2025 Commercialisation to be undertaken by Grand Pharmaceuticals under existing exclusive licensing agreement
Cosmo, Glenmark signs distribution and license pacts for Winlevi in Europe, South Africa EP News Bureau Sep 27, 2023 Cassiopea will receive an upfront payment of $5 million, in addition to double-digit regulatory and sales milestones as well as…
US FDA accepts Glenmark’s IND application for GRC 54276 to proceed with Phase 1/2 clinical study for… EP News Bureau Mar 16, 2023 GRC54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor developed by Glenmark
